Can we personalize treatment for kidney diseases?

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 10, 2009, Pages 1670-1676

  Rovin, Brad H ^a   McKinley, Alison M ^a   Birmingham, Daniel J ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ACUTE GRAFT REJECTION; ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FOCAL GLOMERULOSCLEROSIS; GENE CLUSTER; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE PROLIFERATION; MEDICAL RESEARCH; MEMBRANOUS GLOMERULONEPHRITIS; MICROARRAY ANALYSIS; PAUCI IMMUNE VASCULITIS; PHARMACODYNAMICS; PHARMACOGENETICS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULITIS;

ARYL HYDROCARBON HYDROXYLASES; AZATHIOPRINE; CALCINEURIN; COMPLEMENT C3; COMPLEMENT C4; CYCLOPHOSPHAMIDE; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY DISEASES; LEUKOCYTES, MONONUCLEAR; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, FC;

EID: 73349097240     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04140609     Document Type: Short Survey

References (57)

1. Sarwal M, Chua M, Kambham N, Hsieh S, Satterwhite T, Masek M, Salvatierra O: Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349: 125-138, 2003
2. Zarkhin V, Kambham N, Li L, Kwok S, Hsieh S-C, Salvatierra O, Sarwal M: Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 74: 664-673, 2008
3. Schwab K, Witte D, Aronow B, Devarajan P, Potter SS, Patterson LT: Microarray analysis of focal segmental glomerulosclerosis. Am J Nephrol 24: 438-447, 2004
4. Peterson KS, Huang J-F, Zhu J, D'Agati VD, Liu X, Miller N, Erlander MG, Jackson MR, Winchester RJ: Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 113: 1722-1733, 2004
5. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu C-Y, Nagaraja HN: Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16: 467-473, 2005
6. Richards A, Kavanagh D, Atkinson JP: Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states: The examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 96: 141-177, 2007
7. Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B, Hebert M, Jones KN, Shu Y, Kitzmiller K, Blanchong CA, McBride KL, Higgins GC, Rennebohm RM, Rice RR, Hackshaw K, Roubey RA, Grossman JM, Tsao BP, Birmingham DJ, Rovin BH, Hebert LA, Yu CY: Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): Low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 80: 1037-1054, 2007
8. van Schaik RH: CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 11: 77-98, 2008
9. Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K, Montemurro M, Roots I, Cascorbi I: Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome. Pharmacogenomics J 5: 365-373, 2005
10. Guan S, Huang M, Li X, Chen X, Chan E, Zhou S-F: Intra-and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm Res 23: 1983-1990, 2006
11. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP: Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS clinical trials group study. AIDS 18: 2391-2400, 2004
12. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5: 895-931, 2004
13. Xie H-G, Kim RB, Wood AJJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41: 815-850, 2001
14. Mizutani T: PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35: 99-106, 2003
15. Takada K, Arefayene M, Desta Z, Yarboro CH, Boumdpas DT, Balow JE, Flockhart DA, Illei GG: Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 50: 2202-2210, 2004
16. Cattaneo D, Tankiewicz A, Merlini S, Perico N, Remuzzi G: Pharmacogenetics and pharmacogenomics of immunosuppressive agents: Perspectives for individualized therapy. Personalized Medicine 1: 53-62, 2004
17. Schutz E, Gummert J, Armstrong V, Mohr F, Oellerich M: Azathioprine pharmacogenetics: The relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 34: 199-205, 1996
18. Cattaneo D, Baldelli S, Perico N: Pharmacogenetics of immunosuppressants: Progress, pitfalls and promises. Am J Transplant 8: 1-10, 2008
19. Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, Cattaneo D: C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8: 1127-1141, 2007
20. Girard H, Court MH, Bernard O, Fortier L-C, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C: Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14: 501-515, 2004
21. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y: The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A0) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78: 351-361, 2005
22. Van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers DR, Le Meur Y, van Der Werf M, Mamelok R, van Gelder T: UGT1A9-275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther June 3, 2009 [epub ahead of print]
23. De Jonge H, Kuypers DR: Pharmacogenetics in solid organ transplantation: Current status and future directions. Transplant Rev 22: 6-20, 2008
24. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47: 1048-1052, 2001
25. Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J: The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 14: 665-671, 2004
26. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82: 711-725, 2007
27. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo K, Sugimachi K: Neurotoxicity induced by tacrolimus after liver transplantation: Relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74: 571-572, 2002
28. Harrap S, Tzourio C, Cambien T, Poirier O, Raoux S, Chalmers J, Chapman N, Colman S, Leguennee S, MacMahon S, Neal B, Ohkubo T, Woodward M: The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 42: 297-303, 2003
29. Park CH, Choi HY, Kim BS, Kang SW, Choi KH, Ha SK, Lee HY, Han DS: Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/ deletion polymorphism. Kidney Blood Press Res 29: 216-224, 2006
30. Nonoguchi H, Nakayama Y, Shigai T, Inoue T, Inoue H, Kohda Y, Honda Y, Tomita K: Low-responders to angiotensin II receptor blockers and genetic polymorphism in angiotensin-converting enzyme. Clin Nephrol 68: 209-215, 2007
31. Weekers L, Bouhanick B, Hadjadj S, Gallois Y, Roussel R, Pean F, Ankotche A, Chatellier G, Alhenc-Gelas F, Lefebvre P, Marre M: Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes 54: 2961-2967, 2005
32. Perna A, Ruggeneti P, Testa A, Spoto B, Benini R, Misefari V, Remuzzi G, Zoccali C: ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 57: 274-281, 2000
33. Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, Shahinfar S, Wong PH, Lyle PA, Rossing P, Brenner BM: ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 19: 771-779, 2008
34. Scharplatz M, Puhan MA, Steurer J, Perna A, Bachmann LM: Does the angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? A systematic review. Curr Control Trials Cardiovasc Med 6: 16, 2005
35. Seki N, Hashimoto N, Suzuki Y, Yagui K, Saito Y: Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. Diab Res Clin Pract 72: 135-141, 2005
36. Woo K-T, Lau Y-K, Chan C-M, Wong K-S: Angiotensin-converting enzyme inhibitor versus angiotensin 2 receptor antagonist therapy and the influence of angiotensin-converting enzyme gene polymorphism in IgA nephritis. Ann Acad Med Singapore 37: 372-376, 2008
37. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R: Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67: 1724-1731, 2008
38. Hirano T, Oka K, Takeuchi H, Kozaki K, Matsuno N, Nagao T, Kozaki M, Ichikawa M, Yoshida M, Umezawa Y, Hirata M, Oh-i T, Koga M: Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: Possible implications for individual therapeutic efficacy. Clin Pharmacol Ther 62: 652-664, 1997
39. Hirano T: Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. Int Immunopharmacol 7: 3-22, 2007
40. Hirano T, Akashi T, Keira T, Oka K, Ihoya N, Yoshida H: Clinical impact of cyclosporine cellular pharmacodynamics in minimal change nephrotic syndrome. Clin Pharmacol Ther 68: 532-540, 2000
41. Briggs W, Gimenez L, Samaniego-Picota M, Choi MJ, Nadasdy T, Eustace J, Scheel P: Relationship between lymphocyte and clinical steroid responsiveness in focal segmental glomerulosclerosis. J Clin Pharmacol 40: 115-123, 2000
42. Takeuchi H, Hirano T, Oka K, Mizumoto K, Akashi T, Sakurai E, Degawa T, Uchiyama M, Kozaki K, Matsuno N, Nagao T, Kozaki M: Lymphocyte sensitivity to cyclosporine and tacrolimus in chronic renal failure patients and clinical significance in renal transplantation. Transplant Proc 30: 36-39, 1998
43. Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, Knowler WC, Monroy M, Libermann TA, Karumanchi SA, Thadhani R: Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 30: 638-643, 2007
44. Merchant ML, Perkins B, Boratyn GM, Ficociello LH, Wilkey DW, Barati MT, Bertram CC, Page GP, Rovin BH, Warram JH, Krolewski AS, Klein JB: Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol July 30, 2009 [epub ahead of print]
45. Rovin BH, Zhang X: Biomarkers for lupus nephritis: The quest continues. Clin J Am Soc Nephrol 2009, in press
46. Fiehn C: Early diagnosis and treatment in lupus nephritis: How we can influence the risk for terminal renal failure. J Rheumatol 33: 1464-1466, 2006
47. Faurschou M, Starklint H, Halbert P, Jacobsen S: Prognosis factors in lupus nephritis: Diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 33: 1563-1569, 2006
48. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50: 3934-3940, 2004
49. Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N, Green-Church K, Nagaraja HN, Birmingham DJ, Yu CY, Hebert LA, Rovin BH: Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int 74: 799-807, 2008
50. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1271-1276, 2004
51. Andrews NC: Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 113: 1251-1253, 2004
52. Lee P, Peng H, Gelbart T, Wang L, Beutler E: Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 102: 1906-1910, 2005
53. Tackey E, Lipsky PE, Illei GG: Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13: 339-343, 2004
54. Mongan AE, Ramdahin S, Warrington RJ: Interleukin-10 response abnormalities in systemic lupus erythematosus. Scand J Immunol 46: 406-412, 1997
55. Aringer M, Smolen JS: Cytokine expression in lupus kidneys. Lupus 14: 13-18, 2005
56. Rettie A, Tai G: The pharmacogenomics of warfarin. Mol Interv 6: 223-227, 2006
57. Kamali F, Pirmohamed M: The future prospects of pharmacogenetics in oral anticoagulation therapy. Br J Clin Pharmacol 61: 746-751, 2006